7.42
-0.28(-3.64%)
Currency In USD
| Previous Close | 7.7 |
| Open | 7.64 |
| Day High | 7.94 |
| Day Low | 7.21 |
| 52-Week High | 34.46 |
| 52-Week Low | 4.35 |
| Volume | 33,157 |
| Average Volume | 99,320 |
| Market Cap | 77.64M |
| PE | 0.08 |
| EPS | 94.42 |
| Moving Average 50 Days | 7.47 |
| Moving Average 200 Days | 9.94 |
| Change | -0.28 |
If you invested $1000 in Avalo Therapeutics, Inc. (AVTX) since IPO date, it would be worth $0.4 as of March 14, 2025 at a share price of $7.42. Whereas If you bought $1000 worth of Avalo Therapeutics, Inc. (AVTX) shares 5 years ago, it would be worth $1.52 as of March 14, 2025 at a share price of $7.42.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Avalo Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 24, 2025 12:00 PM GMT
WAYNE, Pa. and ROCKVILLE, Md., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in t
Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 04, 2025 1:00 PM GMT
WAYNE, Pa. and ROCKVILLE, Md. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Exec
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
GlobeNewswire Inc.
Jan 02, 2025 12:00 PM GMT
WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Jennifer Riley as